Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
纳维托克和曲美替尼联合抑制BCL-xL和MEK治疗KRAS或NRAS突变晚期实体瘤的I/II期研究
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-3135
Corcoran, Ryan B; Do, Khanh T; Kim, Jeong E; Cleary, James M; Parikh, Aparna R; Yeku, Oladapo O; Xiong, Niya; Weekes, Colin D; Veneris, Jennifer; Ahronian, Leanne G; Mauri, Gianluca; Tian, Jun; Norden, Bryanna L; Michel, Alexa G; Van Seventer, Emily E; Siravegna, Giulia; Camphausen, Kyle; Chi, Gary; Fetter, Isobel J; Brugge, Joan S; Chen, Helen; Takebe, Naoko; Penson, Richard T; Juric, Dejan; Flaherty, Keith T; Sullivan, Ryan J; Clark, Jeffrey W; Heist, Rebecca S; Matulonis, Ursula A; Liu, Joyce F; Shapiro, Geoffrey I
